Effects of exopolysaccharide from Lactobacillus rhamnosus on human gut microbiota in in vitro fermentation model

Zhu, Yuzhu; Zhou, Jian; Liu, Wei; Pi, Xionge; Zhou, Qingqing; Li, Ping; Zhou, Tao; Gu, Qing

doi:10.1016/j.lwt.2020.110524

Cited by 29 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have indicated EPS may also have application as an anti-obesity treatment [ 141 , 189 ]. The anti-obesity effect of EPS from L. rhamnosus was observed in a mouse model [ 141 ].…”

Section: Health Benefits Of Exopolysaccharidesmentioning

confidence: 99%

Exopolysaccharides of Lactic Acid Bacteria: Production, Purification and Health Benefits towards Functional Food

et al. 2022

View full text Add to dashboard Cite

Lactic acid bacteria (LAB) are capable of synthesising metabolites known as exopolysaccharides (EPS) during fermentation. Traditionally, EPS plays an important role in fermented dairy products through their gelling and thickening properties, but they can also be beneficial to human health. This bioactivity has gained attention in applications for functional foods, which leads them to have prebiotic, immunomodulatory, antioxidant, anti-tumour, cholesterol-lowering and anti-obesity activity. Understanding the parameters and conditions is crucial to optimising the EPS yields from LAB for applications in the food industry. This review provides an overview of the functional food market together with the biosynthesis of EPS. Factors influencing the production of EPS as well as methods for isolation, characterisation and quantification are reviewed. Finally, the health benefits associated with EPS are discussed.

show abstract

“…Studies have indicated EPS may also have application as an anti-obesity treatment [ 141 , 189 ]. The anti-obesity effect of EPS from L. rhamnosus was observed in a mouse model [ 141 ].…”

Section: Health Benefits Of Exopolysaccharidesmentioning

confidence: 99%

Exopolysaccharides of Lactic Acid Bacteria: Production, Purification and Health Benefits towards Functional Food

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Short-chain fatty acids are major fermentation products metabolized by intestinal anerobic bacteria; they have beneficial effects on the human body ( 30 – 32 ). Figure 2 shows that after 24 h of fermentation, the level of SCFAs did not increase.…”

Section: Resultsmentioning

confidence: 99%

A Class IIb Bacteriocin Plantaricin NC8 Modulates Gut Microbiota of Different Enterotypes in vitro

Hang

Liu

et al. 2022

Front. Nutr.

Self Cite

View full text Add to dashboard Cite

The gut microbiota is engaged in multiple interactions affecting host health. Bacteriocins showed the ability of impeding the growth of intestinal pathogenic bacteria and modulating gut microbiota in animals. Few studies have also discovered their regulation on human intestinal flora using an in vitro simulated system. However, little is known about their effect on gut microbiota of different enterotypes of human. This work evaluated the modification of the gut microbiota of two enterotypes (ET B and ET P) by the class IIb bacteriocin plantaricin NC8 (PLNC8) by using an in vitro fermentation model of the intestine. Gas chromatography results revealed that PLNC8 had no influence on the gut microbiota’s production of short-chain fatty acids in the subjects’ samples. PLNC8 lowered the Shannon index of ET B’ gut microbiota and the Simpson index of ET P’ gut microbiota, according to 16S rDNA sequencing. In ET B, PLNC8 enhanced the abundance of Bacteroides, Bifidobacterium, Megamonas, Escherichia-Shigella, Parabacteroides, and Lactobacillus while decreasing the abundance of Streptococcus. Prevotella_9, Bifidobacterium, Escherichia-Shigella, Mitsuokella, and Collinsella were found more abundant in ET P. The current study adds to our understanding of the impact of PLNC8 on the human gut microbiota and lays the groundwork for future research into PLNC8’s effects on human intestinal disease.

show abstract

“…An in vitro fermentation model for investigating exopolysaccharides effect on gut microbiota showed that exopolysaccharides are transformed into short-chain fatty acids. Furthermore, 16S rDNA sequencing elucidated that exopolysaccharides increased the abundance of Ruminococcus, Dorea, Butyricicoccus, and Blautia (Zhu et al, 2021).…”

Section: Cell-culturementioning

confidence: 99%

Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches

et al. 2021

View full text Add to dashboard Cite

Increasing evidence uncovers the involvement of gut microbiota in the metabolism of numerous pharmaceutical drugs. The human gut microbiome harbours 10-100 trillion symbiotic gut microbial bacteria that utilize drugs as substrates for enzymatic processes to alter host metabolism. Thus, microbiota-mediated drug metabolism can change the conventional drug action course and cause inter-individual differences in efficacy and toxicity, making it vital for drug discovery and development. This review focuses on drug biotransformation pathways and discusses different models for evaluating gut microbiota role in drug metabolism.

show abstract

Effects of exopolysaccharide from Lactobacillus rhamnosus on human gut microbiota in in vitro fermentation model

Cited by 29 publications

References 29 publications

Exopolysaccharides of Lactic Acid Bacteria: Production, Purification and Health Benefits towards Functional Food

Exopolysaccharides of Lactic Acid Bacteria: Production, Purification and Health Benefits towards Functional Food

A Class IIb Bacteriocin Plantaricin NC8 Modulates Gut Microbiota of Different Enterotypes in vitro

Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches

Contact Info

Product

Resources

About